| Basics |
| Company: |
Regeneron Pharmaceuticals, Inc. |
| IPO Date: |
April 2, 1991 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$76.56B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$4.13 | 1.81%
|
| Avg Daily Range (30 D): |
$12.07 | 1.75%
|
| Avg Daily Range (90 D): |
$9.84 | 1.31%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.66M |
| Avg Daily Volume (30 D): |
.75M |
| Avg Daily Volume (90 D): |
.67M |
| Trade Size |
| Avg Trade Size (Sh.): |
66 |
| Avg Trade Size (Sh.) (30 D): |
27 |
| Avg Trade Size (Sh.) (90 D): |
27 |
| Institutional Trades |
| Total Inst.Trades: |
10,785 |
| Avg Inst. Trade: |
$17.26M |
| Avg Inst. Trade (30 D): |
$45.68M |
| Avg Inst. Trade (90 D): |
$46.99M |
| Avg Inst. Trade Volume: |
.05M |
| Avg Inst. Trades (Per Day): |
2 |
| Market Closing Trades |
| Avg Closing Trade: |
$34.02M |
| Avg Closing Trade (30 D): |
$86.97M |
| Avg Closing Trade (90 D): |
$91.26M |
| Avg Closing Volume: |
69.96K |
|
|
|
|
| News |
Feb 21, 2025 @ 5:00 PM
Deadline Alert: Regeneron Pharmaceuticals, Inc. (R...
Source: N/A
|
Feb 21, 2025 @ 12:26 AM
ROSEN, LEADING TRIAL ATTORNEYS, Encourages Regener...
Source: N/A
|
Feb 20, 2025 @ 9:00 PM
REGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman...
Source: Bronstein, Gewirtz & Grossman, Llc
|
Feb 20, 2025 @ 6:00 PM
Chronic Spontaneous Urticaria Market to Register I...
Source: Delveinsight
|
Feb 19, 2025 @ 5:00 PM
DEADLINE ALERT for NXT, RVNC, REGN, BIOA: Law Offi...
Source: Law Offices Of Howard G. Smith
|
| Financials |
| |
TTM |
Q4 2024 |
FY 2024 |
|
Basic EPS
|
$40.9
|
$8.54
|
$40.9
|
|
Diluted EPS
|
$38.34
|
$8.11
|
$38.34
|
|
Revenue
|
$ 14.2B
|
$ 3.79B
|
$ 14.2B
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$ 4.41B
|
$ 917.7M
|
$ 4.41B
|
|
Operating Income / Loss
|
$ 3.99B
|
$ 990.2M
|
$ 3.99B
|
|
Cost of Revenue
|
$
|
$
|
$
|
|
Net Cash Flow
|
$ -248.8M
|
$ 477.2M
|
$ -248.8M
|
|
PE Ratio
|
18.27
|
|
|
|
